New Gemcitabine Therapy Findings Has Been Reported by Researchers at Tufts University School of Medicine (Advanced stage pancreatic cancer: novel therapeutic options)
By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Drugs and Therapies are presented in a new report. According to news reporting originating in Boston, Massachusetts, by NewsRx editors, the research stated, "Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, it continues to be a therapeutic challenge. Gemcitabine approved by FDA in 1997, offers modest improvement of tumor-related symptoms and marginal advantage of survival."
The news reporters obtained a quote from the research from the Tufts University School of Medicine, "Many chemotherapeutic agents have been compared against or combined with gemcitabine in randomized Phase III trials and no drug was shown to be superior to single-agent gemcitabine except FOLFIRINOX and nab-paclitaxel plus gemcitabine. On the other hand, efforts to integrate targeted agents such as BAY 12-9566, SCH 66336, bevacizumab, cetuximab, axitinib and sorafenib have been quite dismal despite extensive pre-clinical and clinical research over the last decade in the field of novel agents. To date, erlotinib remains the only biological agent that has demonstrated a small, but significant, added benefit to single agent gemcitabine. However, numerous new agents, including monoclonal antibodies and tyrosine kinase inhibitors, are currently being tested in an attempt to achieve better response, while maintaining a safe toxicity profile."
According to the news reporters, the research concluded: "In this article, the author discusses the management of advanced pancreatic and the current role of novel agents in this setting."
For more information on this research see: Advanced stage pancreatic cancer: novel therapeutic options. Expert Review of Clinical Pharmacology, 2014;7(4):487-98 (see also Drugs and Therapies).
Our news correspondents report that additional information may be obtained by contacting M.W. Saif, Dept. of Medicine and Cancer Center, Tufts Medical Center, Tufts University School of Medicine, 800 Washington Street, Box 245, Boston, MA 02111, United States.
Keywords for this news article include: Boston, Massachusetts, United States, North and Central America, Antimetabolites, Antineoplastics, Antivirals, Drugs, Drugs and Therapies, Gastroenterology, Gemcitabine, Genetics, Immunosuppressive Agents, Oncology, Pancreas, Pancreatic Cancer, Pancreatic Neoplasms, Radiation Sensitizing Agents, Therapy.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC